RecordLens
Menu

Claim review. Product claims

Contradicted

A reliable and applicable record states the opposite.

Purdue's original OxyContin label said that delayed absorption from OxyContin tablets was believed to reduce the drug's abuse liability.

is believed to reduce the abuse liability of a drug
About
Purdue Pharma L.P.
Claim made by
US Senate Committee on the Judiciary, official report
Published
31 July 2007
Original
Testimony of The Honorable John L. Brownlee
Evidence score
88 How it was scored
Last reviewed
25 October 2026

Why this label

The label wording is documented in testimony by the US Attorney for the Western District of VirginiaS1. The same record says Purdue's assertions that OxyContin was less addictive and less subject to abuse and diversion were false, and that the company knew they were falseS1. Purdue pleaded guilty in 2007 to a felony charge of misbranding OxyContin with intent to mislead and defraud physicians and consumersS1. Purdue later pleaded guilty in 2020 to conspiracy to defraud the United States and violate the Food, Drug, and Cosmetic ActS2. The guilty plea is the company's admission, and it contradicts the reduced abuse liability message. The testimony does not date the label sentence. FDA approved OxyContin in December 1995S8, and the testimony says the false marketing began in January 1996S1. Purdue later amended the statementS1.

Current procedural position

Felony misbranding guilty plea by Purdue, with the court proceeding described in the testimony as taking place on 20 July 2007S1. Final.

Record supporting the assessment

Purdue's assertions that OxyContin was less addictive and less subject to abuse and diversion were false
S1 Tier A US Senate Committee on the Judiciary (testimony of the US Attorney for the Western District of Virginia), Testimony of The Honorable John L. Brownlee, 31 July 2007
a felony charge of illegally misbranding OxyContin in an effort to mislead and defraud physicians and consumers
S1 Tier A US Senate Committee on the Judiciary (testimony of the US Attorney for the Western District of Virginia), Testimony of The Honorable John L. Brownlee, 31 July 2007
OxyContin (oxycodone controlled-release) approved
S8 Tier A US Food and Drug Administration, Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention, Last updated 28 August 2026

Conflicting or limiting record

[d]elayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability of a drug.
S1 Tier A US Senate Committee on the Judiciary (testimony of the US Attorney for the Western District of Virginia), Testimony of The Honorable John L. Brownlee, 31 July 2007

Evidence score: 88 of 100

The score grades how well the record establishes this assessment. It is not a score of Purdue Pharma L.P.. Score = source authority + directness + corroboration + procedural accuracy + currency + reproducibility.

ComponentPointsMaxReason
Source authorityIs the source competent to establish the proposition?2630Sworn testimony by the prosecuting US Attorney describes the plea and the falsity of the claims.
DirectnessDoes the source state the proposition or only discuss adjacent facts?1920The testimony quotes the label and calls the related assertions false.
CorroborationDo independent records support the same material point?1215The 2020 DOJ plea on FDCA fraud points the same way.
Procedural accuracyDoes the record settle the procedural state the claim describes?1415A guilty plea is final and is the company's own admission.
CurrencyHas the record been checked against later developments?910Checked against the 2025 plan approval and the 2026 wind down.
ReproducibilityCan a reader locate the passage and repeat the assessment?810The testimony is on the Senate Judiciary site. The plea papers were not read.
Total88100

Timeline

  1. FDA approves OxyContinS8
  2. Purdue begins marketing OxyContin as less addictive, per the testimonyS1
  3. Purdue's guilty plea proceeding, per the testimonyS1
  4. US Attorney testifies before the Senate Judiciary CommitteeS1

Related cases

  • United States v. Purdue (OxyContin misbranding)US District Court for the Western District of Virginia. Criminal. Not confirmed in the records read.Stage: Guilty plea and court proceeding of 20 July 2007, as described by the US AttorneyS1.
    • Felony misbranding plea by the company, with US$600 million in fines, forfeitures and civil recoveriesS1

Revision history

  • Assessment first published with label Contradicted.

Have a record that changes this assessment? See corrections and responses.

Sources

  1. S1Tier A Testimony of The Honorable John L. BrownleeUS Senate Committee on the Judiciary (testimony of the US Attorney for the Western District of Virginia). Government press release. 31 July 2007.Prosecutor's sworn account of the 2007 plea, the label wording and the falsity of the marketing claims. It is not the plea agreement itself.
  2. S8Tier A Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose PreventionUS Food and Drug Administration. Regulator press release. Last updated 28 August 2026.FDA timeline dating the approval of OxyContin to December 1995. It does not quote the original label sentence on abuse liability.Link working, checked 25 October 2026
  3. S2Tier A Opioid Manufacturer Purdue Pharma Pleads Guilty to Fraud and Kickback ConspiraciesUS Department of Justice. Government press release. 24 November 2020.Reports the 2020 plea counts and agreed amounts. It does not report sentencing.Link working, checked 25 October 2026

Other claims about Purdue Pharma L.P.